Skip to site menu Skip to page content

Daily Newsletter

13 December 2024

Daily Newsletter

13 December 2024

Osteotec to distribute Cerapedics’ bone graft products in UK and Ireland

The agreement includes Cerapedics' i-FACTOR Bone Graft Putty and i-FACTOR Bone Graft FLEX FR products.

gullapalli December 12 2024

Osteotec has signed an exclusive agreement for the distribution of Cerapedics' i-FACTOR bone graft portfolio in Ireland and the UK.

The agreement is aligned with Osteotec's mission to improve surgical outcomes in bone repair. The distribution deal refers to products such as the i-FACTOR Bone Graft Putty and i-FACTOR Bone Graft FLEX FR, which are used in spine procedures.

Cerapedics' i-FACTOR portfolio is distinguished by its P-15 osteogenic cell-binding peptide, a unique feature that accelerates new bone formation by attaching and activating osteogenic cells.

This mechanism of action is exclusive to Cerapedics' products and has been clinically validated.

The i-FACTOR Bone Graft, leveraging the P-15 peptide, is the only biologic bone graft composed of a small peptide bound to an anorganic bone mineral. This combination facilitates a surface-bound mechanism that promotes natural bone healing while preventing ectopic bone growth.

Unlike engineered growth factors, i-FACTOR Bone Graft's P-15 peptide specifically activates cells predestined to become osteoblasts.

Effective as of 1 December, the agreement aims to significantly boost sales and revenue while driving the growth of both companies. It also combines Cerapedics' product design with Osteotec's market expertise to foster the adoption of i-FACTOR products in the region.

Cerapedics International general manager Stewart Jefferson said: “This partnership is an important step in our global growth strategy.

“Osteotec’s established market presence and commitment to service excellence make them an ideal partner. Together, we are confident we can deliver effective solutions to surgeons while improving patient outcomes throughout the UK and Ireland.”

Osteotec sales and marketing director Dean Stockwell said: “At Osteotec, we are committed to delivering best-in-class solutions that empower surgeons to achieve optimal patient outcomes.

“Our partnership with Cerapedics enhances our ability to meet the evolving needs of our customers by providing access to advanced biologics.”

In June 2024, Osteotec partnered with TriMed for the distribution of the Osteotec Silicone Finger Implant in the US.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close